You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Anti-CB2 blocking peptide
Discontinued ProductAnti-CB2 blocking peptide (Cat. No. 2388) has been withdrawn from sale for commercial reasons.
Synthetic peptide (NPMKDYMILSGPQK) corresponding to amino acids 19-33 of human cannabinoid receptor 2 (Accession no. P34972). Immunogen used for anti-CB2 (Cat. No. 2231).
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Keywords: Anti-CB2 blocking peptide, Anti-CB2 blocking peptide supplier, Blocking, peptides, cannabinoids, CB2, Receptors, immunogen, 2388, Tocris Bioscience
Citations for Anti-CB2 blocking peptide
Citations are publications that use Tocris products.
Currently there are no citations for Anti-CB2 blocking peptide.
Reviews for Anti-CB2 blocking peptide
There are currently no reviews for this product. Be the first to review Anti-CB2 blocking peptide and earn rewards!
Have you used Anti-CB2 blocking peptide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.